Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2237355 | 0.69 | TSHR (0.43) | TSHRTDP1 | |
| SCHEMBL3410921 | 0.67 | TSHR (0.40) | TSHRTDP1 | |
| SCHEMBL3414497 | 0.67 | — | — | |
| SCHEMBL16332315 | 0.65 | TSHR (0.32) | TSHRTDP1 | |
| SCHEMBL1401767 | 0.64 | TSHR (0.38) | TSHRTDP1 | |
| SCHEMBL5570795 | 0.64 | — | — | |
| SCHEMBL9930552 | 0.64 | TSHR (0.38) | TSHRTDP1 | |
| SCHEMBL14236895 | 0.64 | — | — | |
| SCHEMBL3413807 | 0.64 | TSHR (0.38) | TSHRTDP1 | |
| SCHEMBL3196942 | 0.64 | TSHR (0.38) | TSHRTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090093468-A1 | Peptide Deformylase Inhibitors | ARPIDA A/S (DK) | 2009-04-09 | — | — | US | disclosed |
| US-20070066672-A1 | Benzimidazole derivatives and use thereof as peptide deformylase inhibitors | ARPIDA A/S (DK) | 2007-03-22 | — | — | US | disclosed |
| EP-1732907-A1 | PEPTIDE DEFORMYLASE INHIBITORS | Arpida A/S (DK) | 2006-12-20 | — | — | EP | disclosed |
| WO-2005092872-A1 | PEPTIDE DEFORMYLASE INHIBITORS | ARPIDA A/S (DK) | 2005-10-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070066672-A1 | Benzimidazole derivatives and use thereof as peptide deformylase inhibitors | PDF, MRPL21, PEPD | TSHR 2044/4885TDP1 3197/4885 |
| US-20090093468-A1 | Peptide Deformylase Inhibitors | PDF, PEPD, MRPL21 | TSHR 1829/4885TDP1 2070/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.